Storys zum Thema Genetik

Debiopharm International SA

Swiss-based Debiopharm co-invests in the future of cell therapies on a chip through the latest $25 million Series A round for Mekonos

Lausanne, Switzerland - San Francisco (ots) - Funding to accelerate the development of Mekonos’ System on a Chip (SoC), expand commercial partnerships Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today having invested $4M inMekonos, a biotech company building the future of cell ...

News Direct

Microban® International Announces a New Range of Antiviral Technologies

Abcam; Nautilus Biotechnology, Inc.

As an element of Nautilus' overall reagent development and sourcing strategy, the partnership aims to accelerate research and development, and provide customers with access to Abcam's antibody development technology and expertise

Seattle and Cambridge, England (ots/PRNewswire) - Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences research tools, today announced a ...

Abcam plc

Abcam completes $340m strategic acquisition and expands kit capacity and capability

Cambridge, England (ots/PRNewswire) - - Completing $340m strategic acquisition of BioVision - Expanding facilities in Eugene, further growing kits and assays portfolio - Supporting the growing demand of the sector and accelerating execution of strategic plan Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences reagents and tools, today announces the ...

Debiopharm International SA

DEBIOPHARM ENCOURAGES BREAKTHROUGH CANCER RESEARCH IN JAPAN THROUGH ITS COMPETITIVE JCA MAUVERNAY AWARD

Lausanne, Switzerland (ots) - Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of the 17th annual JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categories: Innovative and/or Disruptive Research –Dr. Shumpei Ishikawa and ...

Micreos

Micreos secures EUR32 million for its endolysin-based platform as sustainable alternative to antibiotics

The Hague, The Netherlands (ots/PRNewswire) - Dutch biotechnology company Micreos announced it has secured another EUR32 million in funding to further develop its endolysin platform technology, based on targeted killing of only unwanted bacteria. This funding round will help Micreos accelerate its clinical ...

Vidac Pharma LTD

Vidac Pharma Ltd Announces Wider Spectrum Authorization Of Its CTCL Phase 2 Clinical Trial

Rehovot, Israel (ots/PRNewswire) - BASED OF THE SATISFACTORY SAFETY DATA OF VIDAC VDA 1102 ON SELECTED PATIENTS VIDAC PHARMA RECEIVED AUTHORIZATION TO WIDEN THE SCOPE OF THE TRIAL TO CTCL WHOLE SPECTRUM OF CONDITIONS. "WE ARE VERY SATISFIED WITH THE RESULTS OF THE FIRST STEP WHICH ON TOP OF THE SAFETY RESULTS GRANTED TO OUR TRIAL A DOSE RANGING PROTOCOL AUTHORIZATION. ...

Vidac Pharma LTD

Vidac Pharma Ltd.: New Chemical Entities Patent Granted

Rehovot, Israel (ots/PRNewswire) - Vidac Pharma Ltd. announces that it was granted a USA Patent for a new chemical family of compounds targeting the HK2-VDAC system developed by the company. The new compounds are hydrophilic and were developed to fit systemic use such as IV, IM and/or Per-Os use. "This is opening the way to explore possible treatment of solid tumors overexpressing HK2 such as Prostate, Pancreas and other ...

Schweizerischer Nationalfonds / Fonds national suisse

Cancerous tumours: how likely are they to metastasise?

Bern (ots) - A very aggressive type of cancer has provided a team of researchers supported by the Swiss National Science Foundation with an answer to the question of which tumour cells are at risk of spreading. Cancer treatment is sometimes complicated by the heterogeneity of the cells that form the tumour mass. The problem is how to identify the few cells that are capable of triggering metastases. Thanks to work carried ...

Abcam plc

Abcam opens new US facility in Boston, MA

Cambridge (ots/PRNewswire) - Supporting accelerated growth of R&D, manufacturing, and commercial activities with new 100,000 sq-ft state-of-the-art facility Reinforcing commitment to the region as Abcam approaches 20 years of US presence Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life sciences reagents and tools, today announces the opening of a major new site in Waltham, MA. The new facility is a central ...

Servier; Nymirum

Servier and Nymirum Announce Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics

Paris (ots/PRNewswire) - Servier, a global independent pharmaceutical Group, and Nymirum, a pioneer in RNA-targeted small molecules, announced today that they have entered into a strategic collaboration to identify and develop RNA-modulatory drugs for the treatment of neurological diseases. Under the collaboration ...

Abcam; Pionyr

Pionyr and Abcam extend partnership to evaluate TREM2-expressing cells in cancer patients

South San Francisco, Calif. and Cambridge, England (ots/PRNewswire) - - The partnership will support the progression of PY314, the first of Pionyr's Myeloid Tuning(TM) antibodies to enter the clinic - Pionyr will use Abcam's EPR20243 clone to evaluate TREM2 levels in tissue samples for potential future development ...

Schweizerischer Nationalfonds / Fonds national suisse

The complex organisation of an ant colony

Bern (ots) - A study on predatory ants, supported by the Swiss National Science Foundation, explains how small differences between individuals can change the collective organisation of the colony. The colonies of social insects are complex systems that are entirely self-organised. Scientists who looked at the demographic, genetic and morphological structure of ant colonies were able to show how this self-organisation ...

Debiopharm International SA

DEBIOPHARM AND UBIX THERAPEUTICS LAUNCH RESEARCH TO DEVELOP A NEW ANTI-CANCER MODALITY - ANTIBODY DEGRADUCER® CONJUGATES

Lausanne, Switzerland, Seoul, Republic of Korea (ots) - Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company and Ubix Therapeutics (en.ubixtrx.com), a South Korea-based biotech company today announced their co-research agreement combining two novel proprietary technologies to specifically ...

Debiopharm International SA

DEBIOPHARM’S CD37 ANTIBODY DRUG CONJUGATE SHOWS PROMISING PHASE II RESULTS FOR THE TREATMENT OF B-CELL MALIGNANCIES

Lausanne, Switzerland (ots) - - Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form of Non-Hodgkin’s Lymphoma (NHL), representing 30-40% of cases. Nearly half of DLBCL patients are not cured by first-line treatment, leaving a large number of patients at risk of worsening disease1 - Naratuximab ...

Shycocan

TNO research shows effectiveness of corona cannon

Rijswijk, Netherlands (ots/PRNewswire) - Addition due to incomplete information in the press release as sent on 4 June 2021 Analyses carried out by TNO in a BSL-3 laboratory cabinet showed that the corona gun had achieved a 94.9% reduction in the Covid -19 virus after 15 minutes. In the laboratory set-up, the (live) virus was located on stainless steel plates at 85 cm from the device. Earlier, the Dutch scientific ...

Merck Healthcare Germany

Merck and BioMed X Institute Extend Collaboration to Continue Novel Research in Oncology and Autoimmunity

Darmstadt, Germany (ots/PRNewswire) - - Merck to support up to six additional research projects at the BioMed X Institute in Heidelberg within the next six years - Call for application for a global crowdsourcing project, 'Regulatory T Cell Dysfunction in Autoimmunity and Inflammaging' Merck, a leading science and ...

Avectas

Avectas announces publication in leading cell therapy journal Cytotherapy of 'A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications'

Dublin (ots/PRNewswire) - SOLUPORE® technology enables the next-generation of gene-modified cell therapies Irish based cell engineering company, Avectas today announces the publication of 'A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy ...

CAS

CAS launches new brand reflecting strategic evolution to empower smarter science

Columbus, Ohio (ots/PRNewswire) - Expanding portfolio of solutions and capabilities addressing growing need for curated scientific data and expertise to accelerate discovery CAS, a division of the American Chemical Society (ACS) that specializes in scientific information solutions, today launched a new brand reflecting the broadening scope of its solutions and ...

Avectas

AVECTAS Leads EUR7.23 million Consortium Awarded Part Funding From Disruptive Technologies Innovation Fund

Dublin (ots/PRNewswire) - Funding to develop high throughput cell engineering technology to manufacture 'off the shelf' cell therapies. Project, led by Avectas in partnership with Bluebridge Technologies and National Institute for Bioprocessing Research and Training (NIBRT), would support Ireland's goal of being at ...

Precision Nanosystems

Precision NanoSystems Announces New Cell Therapy Reagent for Lipid Nanoparticle -based mRNA Delivery to T Cells

Vancouver, Bc (ots/PRNewswire) - Precision NanoSystems (PNI), a global leader in innovative solutions for genetic medicine development, today launched the GenVoy-ILM(TM) T Cell Kit for mRNA to enable lipid nanoparticle (LNP)-based ex vivo gene transfer. Scientists can now use mRNA-LNP to efficiently and reproducibly ...

Debiopharm International SA

DEBIOPHARM COLLABORATES WITH INNOCENTIVE FOR THE LAUNCH OF A GLOBAL CHALLENGE TO DEVELOP A SINGLE-DOSE mRNA COVID-19 VACCINE

Lausanne, Switzerland (ots) - - Currently approved COVID-19 vaccines based on messenger RNA (mRNA) technology require two injections, given several weeks apart, for optimal protection against the virus - Debiopharm has launched a vaccine innovation challenge to a pool of international “problem Solvers” within ...

Vidac Pharma LTD

Vidac Pharma Secures EUR 20m Capital Commitment From GEM

Ness-Ziona, Israel (ots/PRNewswire) - Vidac Pharma LTD (Vidac) a clinical-stage Israel biopharmaceutical company, announced today that it has signed an agreement with GEM Global Yield LLC SCS ("GEM") a Luxemburg-based private alternative investment group for a EUR 20 million capital commitment. Under the agreement, GEM commits to provide Vidac with a share subscription facility of up to EUR 20 million for a 36-month term ...

Schweizerischer Nationalfonds / Fonds national suisse

Novel antibiotic deceives bacteria through mimicry

Bern (ots) - Most antibiotics need to penetrate their target bacteria. But Darobactin, a newly discovered compound, is much too large to do so. Nonetheless, it kills many antibiotic-resistant pathogens - by exploiting a tiny weak spot on their surface. Basel researchers have now revealed the amazing mechanism at play and thereby opened the door to developing completely new medicines. An increasing number of bacterial ...